Allogeneic DiseaseAPOLLONCT05579678
APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation
An observational study of Allogeneic Disease, run by University of Alberta at 1 site in Canada.
Trial summary
People who undergo allogeneic bone marrow transplant for blood cancers receive the highest chemotherapy doses possible that humans can receive and still survive. As a result, they have devastating side effects during the procedure and for many years afterwards. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Allogeneic Disease
- What is being tested?
- Supportive nursing, nutritional and physical activity with a handheld 'app'
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 45 participants
- Where
- 1 siteCanada
- Study dates
- 20 Nov 2022to 31 Aug 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: individuals scheduled to undergo allogeneic transplantation
Who may be able to join
- eligible for allogeneic transplantation
Who cannot join
- none
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
University of Alberta
Edmonton, Alberta, T6G 1C9
Edith Pituskin, 7804328221, pituskin@ualberta.ca
About this study
People who undergo allogeneic bone marrow transplant for blood cancers receive the highest chemotherapy doses possible that humans can receive and still survive. As a result, they have devastating side effects during the procedure and for many years afterwards. Damage to organs and muscles cause long-lasting physical weakness and the psychological experience is severe enough to be termed 'post traumatic stress disorder' that also lasts for many years. These effects are worsened by the fact that most Canadians live several hours away from treatment and transplant centers, leaving them entirely on their own to manage these difficult long term effects. The APOLLO team will perform a qualitative study to learn the experiences of people undergoing allogeneic bone marrow transplant while they receive access to a supportive care computer 'app' and telephone support from nursing, exercise and nutrition experts. In this way, the APOLLO team will learn the most helpful type and timing of supportive care from those who know best.
- Conditions
- Allogeneic Disease
- Being tested
- Supportive nursing, nutritional and physical activity with a handheld 'app'
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Supportive nursing, nutritional and physical activity with a handheld 'app'Behavioural
Supportive nursing, nutritional and physical activity with a handheld 'app'
What is being measured
The primary outcome is the main question the study is designed to answer.
Title: Acceptability of a multimodal supportive care
Description: Questionnaire to assess usefulness of a multimodal supportive care App that includes care navigation (nursing, exercise, nutrition)
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2022
- Study start20 Nov 2022
- Primary completion31 Aug 2026 (estimated)
- Study completion31 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Allogeneic DiseaseStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05579678
- Sponsor's protocol ID
- HREBA.CC-22-0164
- Acronym
- APOLLO
- Status last verified
- May 2026
- First submitted
- 20 Sep 2022
- Last updated
- 11 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Pituskin E, Foulkes S, Skow RJ, McMurtry T, Kruger C, Bates JE, Lamoureux D, Brandwein J, Lieuw E, Wu C, Zhu N, Wang P, Sawler D, Taparia M, Hamilton M, Comfort-Riddle T, Meyer T, Gyenes GT, Paterson I, Prado CM, Haykowsky MJ, Greiner JG, McNeely ML, Tandon P, Thompson RB. Rationale and design of APOLLO: a personalized rehAbilitation PrOgram in aLLOgeneic bone marrow transplantation. BMC Cancer. 2025 Jan 28;25(1):163. doi: 10.1186/s12885-025-13502-8.
PubMed 39875816
Study at a glance
From the registry record, last updated by the sponsor on 11 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation
- ClinicalTrials.gov ID
- NCT05579678
- Acronym / sponsor ID
- APOLLO / HREBA.CC-22-0164
- Conditions
- Allogeneic Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Study start
- 20 Nov 2022 (actual)
- Primary completion
- 31 Aug 2026 (estimated)
- Study completion
- 31 Aug 2026 (estimated)
- First posted
- 14 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
People who undergo allogeneic bone marrow transplant for blood cancers receive the highest chemotherapy doses possible that humans can receive and still survive. As a result, they have devastating side effects during the procedure and for many years afterwards. Damage to organs and muscles cause long-lasting physical weakness and the psychological experience is severe enough to be termed 'post traumatic stress disorder' that also lasts for many years. These effects are worsened by the fact that most Canadians live several hours away from treatment and transplant centers, leaving them entirely on their own to manage these difficult long term effects. The APOLLO team will perform a qualitative study to learn the experiences of people undergoing allogeneic bone marrow transplant while they receive access to a supportive care computer 'app' and telephone support from nursing, exercise and nutrition experts. In this way, the APOLLO team will learn the most helpful type and timing of supportive care from those who know best.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- individuals scheduled to undergo allogeneic transplantation
Key inclusion criteria (1 listed)
- eligible for allogeneic transplantation
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Supportive nursing, nutritional and physical activity with a handheld 'app'Supportive nursing, nutritional and physical activity with a handheld 'app' | Behavioural | – |
Primary outcome
Title: Acceptability of a multimodal supportive care
Time frame: 1 year
Description: Questionnaire to assess usefulness of a multimodal supportive care App that includes care navigation (nursing, exercise, nutrition)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 May 2026.
- Derived from this study: PubMed 39875816Pituskin E, Foulkes S, Skow RJ, McMurtry T, Kruger C, Bates JE, Lamoureux D, Brandwein J, Lieuw E, Wu C, Zhu N, Wang P, Sawler D, Taparia M, Hamilton M, Comfort-Riddle T, Meyer T, Gyenes GT, Paterson I, Prado CM, Haykowsky MJ, Greiner JG, McNeely ML, Tandon P, Thompson RB. Rationale and design of APOLLO: a personalized rehAbilitation PrOgram in aLLOgeneic bone marrow transplantation. BMC Cancer. 2025 Jan 28;25(1):163. doi: 10.1186/s12885-025-13502-8.
- Individual participant dataSharing planned: Undecided
Related trials for Allogeneic Disease
RecruitingPhase 2
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
Graft-Versus-Host Disease, GVHD
RecruitingObservational study
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Graft-versus-leukemia, Graft vs Host Disease
RecruitingPhase 1
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy
Active, not recruitingPhase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders
Not yet recruitingPhase 1
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Allogeneic Disease, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Edith Pituskin, PhD (7804328221, pituskin@ualberta.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Title: Acceptability of a multimodal supportive care (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05579678, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2026.